Published in Ann Oncol on January 01, 2005
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch (2008) 2.78
Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol (2006) 2.17
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist (2010) 1.26
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer (2009) 1.18
IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B (2006) 1.12
FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis (2012) 1.01
Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification. Diagn Pathol (2011) 0.99
ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis (2009) 0.99
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med (2011) 0.99
VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J Gastroenterol (2008) 0.98
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer (2013) 0.98
EGFR controls IQGAP basolateral membrane localization and mitotic spindle orientation during epithelial morphogenesis. EMBO J (2014) 0.96
Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Br J Cancer (2008) 0.92
A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer (2007) 0.91
Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience (2014) 0.91
Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch (2007) 0.91
Cell surface markers in colorectal cancer prognosis. Int J Mol Sci (2010) 0.90
Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med (2016) 0.90
Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system. Onco Targets Ther (2013) 0.89
Fascin expression in colorectal carcinomas. Clinics (Sao Paulo) (2010) 0.88
Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale J Biol Med (2011) 0.88
Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer (2013) 0.87
Phthalocyanine-peptide conjugates for epidermal growth factor receptor targeting. J Med Chem (2012) 0.86
Impact of EGFR expression on colorectal cancer patient prognosis and survival: a response. Ann Oncol (2005) 0.85
Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. Contemp Oncol (Pozn) (2013) 0.85
An EGFR targeted PET imaging probe for the detection of colonic adenocarcinomas in the setting of colitis. Theranostics (2014) 0.85
EGFR Overexpressed in Colonic Neoplasia Can be Detected on Wide-Field Endoscopic Imaging. Clin Transl Gastroenterol (2015) 0.84
Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer. Oncotarget (2017) 0.84
Integrating anti-EGFR therapies in metastatic colorectal cancer. J Gastrointest Oncol (2013) 0.84
EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. Int J Mol Sci (2013) 0.83
K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer. Int J Colorectal Dis (2009) 0.83
Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. J Oncol (2009) 0.82
Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. Br J Cancer (2015) 0.82
Optical imaging probes in oncology. Oncotarget (2016) 0.81
Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen. Transl Oncol (2013) 0.81
Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. Br J Cancer (2014) 0.81
Novel KRAS gene mutations in sporadic colorectal cancer. PLoS One (2014) 0.81
Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer (2014) 0.80
Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. PLoS One (2016) 0.80
Colorectal cancer chemoprevention by mesalazine and its derivatives. J Biomed Biotechnol (2012) 0.80
Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. Biomed Res Int (2016) 0.79
SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. Oncogenesis (2015) 0.79
Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer. J Transl Med (2016) 0.79
Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node-positive rectal cancer. J Gastrointest Surg (2012) 0.79
Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer. PLoS One (2015) 0.79
Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival. PLoS One (2014) 0.79
Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy. Int J Mol Sci (2015) 0.78
Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. Onco Targets Ther (2012) 0.78
Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis. Neoplasia (2010) 0.78
p85α promotes nucleolin transcription and subsequently enhances EGFR mRNA stability and EGF-induced malignant cellular transformation. Oncotarget (2016) 0.78
Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases. Br J Cancer (2014) 0.78
EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis. Oncogene (2017) 0.77
Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. Oncotarget (2015) 0.77
Epidermal growth factor receptor mediated proliferation depends on increased lipid droplet density regulated via a negative regulatory loop with FOXO3/Sirtuin6. Biochem Biophys Res Commun (2015) 0.77
Reduction of G0 phase cells of colon cancer caco-2 cells may enhance 5-fluorouracil efficacy. J Biomed Res (2010) 0.77
VEGF and dual-EGFR inhibition in colorectal cancer. Cell Cycle (2015) 0.76
The pattern of epidermal growth factor receptor variation with disease progression and aggressiveness in colorectal cancer depends on tumor location. Oncol Lett (2012) 0.76
Concomitant tumor expression of EGFR and TATI/SPINK1 associates with better prognosis in colorectal cancer. PLoS One (2013) 0.76
Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells. PLoS One (2013) 0.76
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. Onco Targets Ther (2009) 0.76
Cetuximab in the management of colorectal cancer. Biologics (2007) 0.76
miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling. Sci Rep (2016) 0.76
p120-catenin down-regulation and epidermal growth factor receptor overexpression results in a transformed epithelium that mimics esophageal squamous cell carcinoma. Am J Pathol (2015) 0.75
Visualizing epithelial expression of EGFR in vivo with distal scanning side-viewing confocal endomicroscope. Sci Rep (2016) 0.75
Combination of metformin and 5-aminosalicylic acid cooperates to decrease proliferation and induce apoptosis in colorectal cancer cell lines. BMC Cancer (2016) 0.75
Targeting of the epidermal growth factor receptor with mesoporphyrin IX-peptide conjugates. J Porphyr Phthalocyanines (2016) 0.75
Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies. World J Gastroenterol (2013) 0.75
The level of epidermal growth factor receptors expression is correlated with the advancement of colorectal adenoma: validation of a surface biomarker. Oncotarget (2017) 0.75
Extracellular matrix gene expression profiling using microfluidics for colorectal carcinoma stratification. Biomicrofluidics (2016) 0.75
DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer. Cancer Med (2017) 0.75
Management of dermatologic toxicities related to epidermal growth factor receptor inhibitor therapy across Europe: can we get a consensus? Ecancermedicalscience (2011) 0.75
Relevance of EGFR expression in colorectal cancer. Ann Oncol (2005) 0.75
The paradoxical functions of EGFR during breast cancer progression. Signal Transduct Target Ther (2017) 0.75
Radiographic and endoscopic regression of metastatic gastric cancer to the colon in the setting of 5-aminosalicylic acid use. J Gastrointest Oncol (2016) 0.75
The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines. Cancer Cell Int (2014) 0.75
Effect of non-alcoholic liver disease on recurrence rate and liver regeneration after liver resection for colorectal liver metastases. Curr Oncol (2017) 0.75
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood (1995) 16.81
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med (1996) 11.76
Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet (1985) 8.35
Uncertainty in predictions of the climate response to rising levels of greenhouse gases. Nature (2005) 7.46
Immunisation against heterologous type II collagen induces arthritis in mice. Nature (1980) 7.08
Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet (1998) 6.20
Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst (1999) 5.92
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Representation of manipulable man-made objects in the dorsal stream. Neuroimage (2000) 4.05
Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99
The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res (1999) 3.83
Attribute-based neural substrates in temporal cortex for perceiving and knowing about objects. Nat Neurosci (1999) 3.83
Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet (1999) 3.81
Distributed representation of objects in the human ventral visual pathway. Proc Natl Acad Sci U S A (1999) 3.76
Properties and mechanisms of perceptual priming. Curr Opin Neurobiol (1998) 3.69
Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol Aging (2001) 3.48
Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med (1999) 3.43
What do gastroenterologists in Europe tell cancer patients? Lancet (1993) 3.42
The effect of face inversion on activity in human neural systems for face and object perception. Neuron (1999) 3.13
Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst (1995) 3.03
Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol (1994) 2.94
Health spending in 1998: signals of change. The Health Accounts Team. Health Aff (Millwood) (2000) 2.92
Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry (1976) 2.89
Ontogeny of orientation flight in the honeybee revealed by harmonic radar. Nature (2000) 2.86
A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. Neuron (1999) 2.82
Determination of oestrogen receptors by enzyme immunoassay. Technical differences between laboratories and their consequences. Eur J Cancer (1994) 2.80
How easy is it to contact the duty medical doctor responsible for acute admissions? BMJ (1990) 2.80
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer (2006) 2.75
Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med (1995) 2.74
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.66
Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med (1998) 2.65
Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol (1972) 2.60
Attributable risk estimation in case-control studies. Epidemiol Rev (1994) 2.60
Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly. Lancet (1978) 2.56
Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J Biol Chem (1975) 2.51
Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet (1986) 2.50
Attributable risk: advantages of a broad definition of exposure. Am J Epidemiol (1994) 2.45
Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. J Neurosci (1999) 2.41
Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis (2006) 2.40
Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med (1997) 2.40
Modulation of emotion by cognition and cognition by emotion. Neuroimage (2007) 2.36
Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS) Am J Clin Pathol (1998) 2.35
WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene (2001) 2.32
Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS (1996) 2.28
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol (2001) 2.24
Internal jugular vein thrombosis: outcome and risk factors. QJM (2010) 2.24
Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. N Engl J Med (1991) 2.21
Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatr Pulmonol (2001) 2.20
Human erythroid 5-aminolevulinate synthase: promoter analysis and identification of an iron-responsive element in the mRNA. EMBO J (1991) 2.18
Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol (2003) 2.15
Renal function, cytogenetic measurements, and sexual development in adolescents in relation to environmental pollutants: a feasibility study of biomarkers. Lancet (2001) 2.13
Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med (1994) 2.12
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer (2006) 2.11
Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy (2013) 2.10
Risk factors for esophageal cancer in Shanghai, China. I. Role of cigarette smoking and alcohol drinking. Int J Cancer (1994) 2.09
Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol (1991) 2.08
Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol (1993) 2.07
Training physicians in counseling about smoking cessation. A randomized trial of the "Quit for Life" program. Ann Intern Med (1989) 2.07
Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol (2009) 2.06
The rhythm of the heart in active elderly subjects. Am Heart J (1980) 2.02
Reference values for self-recorded blood pressure: a meta-analysis of summary data. Arch Intern Med (1998) 2.01
Neuromuscular fatigue differs following unilateral vs bilateral sustained submaximal contractions. Scand J Med Sci Sports (2011) 2.00
Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging (Milano) (1991) 1.93
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol (2010) 1.91
Nocturnal blood pressure fall on ambulatory monitoring in a large international database. The "Ad Hoc' Working Group. Hypertension (1997) 1.90
Sialic acid in the lipopolysaccharide of Haemophilus influenzae: strain distribution, influence on serum resistance and structural characterization. Mol Microbiol (1999) 1.88
Endoscopist-directed propofol administration versus anesthesiologist assistance for colorectal cancer screening: a cost-effectiveness analysis. Endoscopy (2012) 1.82
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst (1990) 1.81
Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol (2004) 1.81
Use of the complete genome sequence information of Haemophilus influenzae strain Rd to investigate lipopolysaccharide biosynthesis. Mol Microbiol (1996) 1.79
Are child-, adolescent-, and adult-onset depression one and the same disorder? Biol Psychiatry (2001) 1.79
Nasopharyngeal carcinomas: an update. Eur J Cancer (2003) 1.78
Liver regeneration in dogs: morphologic and chemical changes. J Surg Res (1978) 1.78
Bradycardia, ventricular pauses, syncope, and sports. Lancet (1984) 1.77
Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med (1994) 1.77
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer (2002) 1.76
Antioxidant capacity, vitamin C, phenolics, and anthocyanins after fresh storage of small fruits. J Agric Food Chem (1999) 1.73
Three-dimensional structure of a mouse-adapted type 2/type 1 poliovirus chimera. EMBO J (1991) 1.72
Spleen size: how well do linear ultrasound measurements correlate with three-dimensional CT volume assessments? Br J Radiol (2002) 1.71
Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol (2008) 1.70
The position of phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae affects binding and sensitivity to C-reactive protein-mediated killing. Mol Microbiol (2000) 1.70
Diacylglycerols and phosphatidates: which molecular species are intracellular messengers? Trends Biochem Sci (1998) 1.69
Polymerase chain reaction for detection of verocytotoxigenic Escherichia coli isolated from animal and food sources. Mol Cell Probes (1992) 1.67
The protein tyrosine kinase p56lck inhibits CD4 endocytosis by preventing entry of CD4 into coated pits. J Cell Biol (1992) 1.67
Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck (1991) 1.66
Equity in access to exercise tolerance testing, coronary angiography, and coronary artery bypass grafting by age, sex and clinical indications. Heart (2001) 1.66
Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer (2006) 1.66
Added value of molecular targeted agents in oncology. Ann Oncol (2011) 1.65